Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review
- PMID: 27546965
- PMCID: PMC4982964
- DOI: 10.1016/j.mjafi.2016.06.004
Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review
Abstract
Background: Pioglitazone has better cardiovascular outcomes and a questionable relationship with bladder carcinoma in diabetes mellitus, type II (DM-2). We sought to evaluate the role of pioglitazone in the Indian population.
Methods: This is a retrospective study at an academic medical center in India. All DM-2 patients in 2008 with a new prescription of pioglitazone were age- and gender-matched with non-users. We excluded patients with gestational DM or DM type I. They were followed forward for five years and demographic data, micro- and macro-vascular complications, mortality, and bladder carcinoma were recorded. Two-tailed p ≤ 0.05 was considered statistically significant.
Results: Two cohorts of 260 patients, with mean age of 58 ± 11 years with 413 (79.4%) males, were followed for five years. Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. HbA1c was not different between groups. Over five years, pioglitazone users had lesser retinopathy and myocardial infarctions (all p < 0.01). Five cases of bladder carcinoma were noted, all in the pioglitazone group, however without statistical significance. Baseline variables, including mean daily pioglitazone dose, were not statistically different between patients with and without bladder carcinoma. Nephropathy and MI were independent predictors for development of bladder carcinoma within pioglitazone users.
Conclusions: Pioglitazone users had significantly lesser myocardial infarctions and retinopathy despite more difficult to control DM 2. In an age- and gender-matched cohort of users and non-users, pioglitazone did not contribute to development of bladder cancer in the Indian population.
Keywords: Bladder carcinoma; Diabetes mellitus type-2; Pioglitazone; Thiazolidinedione; Vascular complications.
Figures
Similar articles
-
Bladder cancer with pioglitazone: A case-control study.Diabetes Metab Syndr. 2022 Nov;16(11):102637. doi: 10.1016/j.dsx.2022.102637. Epub 2022 Oct 8. Diabetes Metab Syndr. 2022. PMID: 36270237
-
Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study.Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):639-43. doi: 10.4103/2230-8210.163187. Indian J Endocrinol Metab. 2015. PMID: 26425474 Free PMC article.
-
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996. JAMA. 2015. PMID: 26197187
-
Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?J Formos Med Assoc. 2012 Mar;111(3):123-31. doi: 10.1016/j.jfma.2011.10.003. Epub 2012 Feb 15. J Formos Med Assoc. 2012. PMID: 22423665 Review.
-
Pioglitazone and cancer: angel or demon?Curr Pharm Des. 2013;19(27):4913-29. doi: 10.2174/13816128113199990294. Curr Pharm Des. 2013. PMID: 23278487 Review.
Cited by
-
Effects of thiazolidinedione in patients with active bladder cancer.BJU Int. 2018 Feb;121(2):244-251. doi: 10.1111/bju.14009. Epub 2017 Sep 23. BJU Int. 2018. PMID: 28872778 Free PMC article.
-
Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study.Int J Med Sci. 2018 Jan 8;15(3):228-237. doi: 10.7150/ijms.22408. eCollection 2018. Int J Med Sci. 2018. PMID: 29483814 Free PMC article.
-
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.Graefes Arch Clin Exp Ophthalmol. 2024 Mar;262(3):717-752. doi: 10.1007/s00417-023-06236-5. Epub 2023 Sep 20. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37728754 Review.
References
-
- Levin D., Bell S., Sund R. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58(March (3)):493–504. - PubMed
-
- Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. - PubMed
-
- Ryder R.E., Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit Diabet Med. 2015;32(March (3)):305–313. - PubMed
-
- Lu C.J., Sun Y., Muo C.H., Chen R.C., Chen P.C., Hsu C.Y. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovasc Dis. 2013;36(2):145–151. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources